Mark Kessel

Learn More
DIAGNOSTIC TESTS CONSTITUTE 3 TO 5% OF HEALTH CARE SPENDING BUT INFLU ence ~70% of health care decisions (1). Furthermore, less than 5% of annual spending on R&D is allocated to diagnostics for neglected diseases (2)—tropical infections common in underdeveloped countries, such as malaria, leishmaniasis, and tuberculosis (TB) (3). Last month, the United(More)
27 cost of bringing a new drug to market has continued to rise and is now estimated to exceed $1 billion. Even though the industry cites scientific breakthroughs, the timeline for developing a drug and getting it to market has not declined and can take as long as 15 years. A major reason that big pharma must limit the number of compounds it introduces into(More)
VOLUME 33 NUMBER 5 MAY 2015 NATURE BIOTECHNOLOGY Mark D. Perkins and Mark Kessel are at FIND (Foundation for Innovative New Diagnostics), Geneva, Switzerland. e-mail: settings, and serving and maintaining these laboratories to function at a high level has been an enormous task at which many senior virologists have labored. The role(More)
VOLUME 33 NUMBER 9 SEPTEMBER 2015 NATURE BIOTECHNOLOGY test that would distinguish bacterial and viral infections by 2020. Regretfully, like other initiatives undertaken by the United States and other bodies dealing with world health issues, this goal is not likely, in and of itself, to result in the development and uptake of diagnostics appropriate for(More)
I wasn’t that long ago that the pharmaceutical industry was considered among the most respected industries and Merck (Whitehouse Station, NJ, USA) the most admired corporation in the United States. This is in sharp contrast to consumer attitudes today, when the industry’s reputation is not much better than that of the financial sector or tobacco companies1.(More) Vol 3 April 2015 e195 of diagnostics for global health should collaborate to leverage their respective resources and expertise, thereby enhancing the likelihood of development of HCV diagnostics. A broad coalition of stakeholders such as diagnostic-focused productdevelopment partnerships, donors, governments, WHO, and Ministries(More)
C worldwide market turmoil and deteriorating economic conditions are not doing cash-hungry biotechs any favors. Neither is investors’ lack of appetite for biotech initial public offerings (IPOs): last year, just 12 biotechs went public (down from 19 in 2010), with 8 of those ending the year trading below their IPO price (Table 1). All of this means that(More)